There is no single fixed Spravato startup cost.
For an existing psychiatry or behavioural health practice, the biggest expenses are usually not REMS enrollment itself. The real financial commitment comes from treatment space, monitoring equipment, staffing, payer setup, medication acquisition, Prior Authorization work, billing infrastructure, and enough working capital to operate while waiting for reimbursement.
If your practice already has providers, clinical space, and basic infrastructure, the incremental startup cost may be manageable. If you are building a new location specifically around Spravato, the investment can be considerably higher.
The most important question is not simply, “How much does it cost to start?”
It is, “How much capital do we need before the program begins producing predictable cash flow?”
A realistic Spravato Practice Cost should include six areas:
Ignoring any one of these can create an expensive problem after launch.
SPRAVATO can only be administered in a healthcare setting certified under the SPRAVATO REMS.
The outpatient setting must have trained staff, appropriate procedures, an onsite prescriber during administration and monitoring, pulse oximetry, and the ability to monitor each patient for at least two hours after treatment.
For an existing practice, this may require only modest operational changes.
For a new Spravato Treatment Program, costs may include:
The mistake is spending heavily on aesthetics while overlooking patient flow. A beautiful room that can only support one patient at a time may limit revenue more than it helps the program.
Medication acquisition is one of the largest financial considerations, especially under Buy and Bill.
SPRAVATO is supplied as 28 mg nasal spray devices. A 56 mg dose uses two devices, while an 84 mg dose uses three.
Public 2026 NADAC-based pricing data has placed individual 28 mg devices in roughly the low-$400 range. Your actual acquisition cost can differ based on distributor arrangements, contracts, and purchasing terms.
This is why clinics should never build a Buy and Bill model using a generic internet price.
Before purchasing medication, determine:
A difference of even $50 to $100 per treatment becomes meaningful once a practice is treating dozens of patients each week.
Spravato requires more than provider time during the initial evaluation.
Someone must manage:
Prior Authorization alone creates substantial administrative expense. The AMA reported in 2026 that practices complete an average of 40 PAs per physician per week, consuming about 13 hours of physician and staff time.
That matters when estimating Spravato Startup Cost.
A program may appear profitable on paper until the owner realizes highly paid clinical staff are spending hours every week calling payers.
This is one reason practices outsource Spravato billing and Prior Authorization instead of adding another full-time internal employee.
A practice can complete REMS enrollment and still be unable to generate predictable insurance revenue.
Before launch, determine whether your providers and location are properly enrolled with the payers you intend to bill.
You also need to know:
Starting without this information creates one of the worst financial situations for a new program: patients are ready, staff are ready, medication has been purchased, but claims cannot be paid correctly.
Working capital is where startup economics become serious.
Under Buy and Bill, the practice purchases medication before receiving insurance reimbursement.
Consider a clinic starting with only a handful of induction patients. During the initial treatment period, those patients may have multiple treatment visits each week. Medication purchases, staffing, and operating costs therefore accumulate well before every claim has been paid.
Your working-capital calculation should consider:
Drug Cost + Payroll + Facility Overhead + Billing Expenses + Expected Payment Delay
Do not calculate working capital based only on one week of medication.
Plan around your actual payer payment cycle and enough financial cushion to absorb denials, authorization delays, and underpayments.
Not necessarily.
For many new programs, building an internal Spravato-specific revenue cycle team is more expensive than outsourcing the work.
Our Spravato Billing Services are designed to simplify:
When you work with a dedicated Spravato Billing Company like Finnastra, you can build the revenue cycle around patient volume instead of hiring several people before the program has matured.
They calculate potential revenue before calculating cash-flow exposure.
A spreadsheet may show strong reimbursement per treatment.
But that does not tell you:
A financially sound Spravato program answers those questions before the first medication order.
As a leading Spravato Billing Services Company, Finnastra helps practices build the financial side of the program before revenue is at risk.
We help providers:
The objective is not simply to lower startup costs.
It is to make sure the money you invest has a clear path back to reimbursement.
REMS certification itself is not usually the major financial burden. The larger expenses are operational readiness, staffing, treatment space, medication acquisition, and revenue-cycle infrastructure.
For Buy and Bill practices, medication acquisition and working capital can become the largest exposure. Staffing and administrative overhead are also significant.
Yes. Existing practices may already have much of the required infrastructure, but they still need REMS readiness, payer verification, Prior Authorization, medication access, monitoring workflows, and billing setup.
Yes. Payer coverage, acquisition cost, expected reimbursement, and billing requirements should be understood before committing significant capital to medication inventory.
Yes. Finnastra helps practices evaluate payer readiness, Buy and Bill workflows, Prior Authorization, billing requirements, and revenue-cycle processes before and after launch.
Spravato can become an important clinical and revenue service line, but only when the economics are understood before launch.
Your Spravato Practice Cost is not simply the price of equipment or medication. It includes the people, payer processes, working capital, billing infrastructure, and follow-up required to turn treatment into collected revenue.
Practices searching for a Top Spravato Billing Company in U.S. or the Best Spravato Billing Company in U.S. should look for a partner that understands those economics, not simply how to submit a claim.
Finastra supports Spravato practices from setup through reimbursement so providers can invest with greater visibility and build a program designed to remain financially sustainable as patient volume grows.
